Last reviewed · How we verify

Triptorelin Embonate — Competitive Intelligence Brief

Triptorelin Embonate (Triptorelin Embonate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GnRH agonist. Area: Oncology.

phase 3 GnRH agonist GnRH receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Triptorelin Embonate (Triptorelin Embonate) — Marco Lorenzo Bonu. Triptorelin Embonate is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH) that acts as a potent agonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Triptorelin Embonate TARGET Triptorelin Embonate Marco Lorenzo Bonu phase 3 GnRH agonist GnRH receptor
Lupron leuprorelin Accord Healthcare S.L.U. marketed Gonadotropin Releasing Hormone Receptor Agonist GnRH receptors 1985-01-01
Micronor norethisterone Johnson & Johnson marketed Progestin GnRH receptors 1962-01-01
Triptorelin (GnRH agonists) Triptorelin (GnRH agonists) University of Pisa marketed GnRH agonist GnRH receptor (GNRHR)
Ultra-Long GnRH Agonists + Letrozole Ultra-Long GnRH Agonists + Letrozole University of Palermo marketed GnRH agonist + aromatase inhibitor combination GnRH receptor; aromatase (CYP19A1)
Agonist GnRH; estradiol Valerate; progesterone Agonist GnRH; estradiol Valerate; progesterone Instituto Valenciano de Infertilidad, IVI VALENCIA marketed Hormone combination therapy; GnRH agonist with steroid hormones GnRH receptor; estrogen receptor; progesterone receptor
LhRH-antagonist LhRH-antagonist Turku University Hospital marketed GnRH/LhRH antagonist GnRH receptor (LhRH receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (GnRH agonist class)

  1. Takeda · 4 drugs in this class
  2. Abbott · 3 drugs in this class
  3. Ipsen · 3 drugs in this class
  4. Changchun GeneScience Pharmaceutical Co., Ltd. · 3 drugs in this class
  5. University of Pisa · 2 drugs in this class
  6. Chong Qing Reproducive and Genetic Institute · 1 drug in this class
  7. Chesapeake Urology Research Associates · 1 drug in this class
  8. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
  9. Enteris BioPharma Inc. · 1 drug in this class
  10. Colorado Center for Reproductive Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Triptorelin Embonate — Competitive Intelligence Brief. https://druglandscape.com/ci/triptorelin-embonate. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: